Gert van der Hoek
In Memoriam - Editor, Senior Moderator
Highly virulent, drug-resistant P. aeruginosa strain identified in Ohio
Perez F. - Antimicrob Agents Chemother. 2014;doi:10.1128/AAC.02372-14.
August 17, 2014
Researchers have identified a highly virulent, multidrug-resistant form of Pseudomonas aeruginosa in patient samples in a health care system in Ohio, according to a report in Antimicrobial Agents and Chemotherapy
The pathogen produced metallo-beta-lactamase (MBL), which has remained uncommon in the United States, but is an emerging problem in P. aeruginosa in many other countries.
?Currently, [metallo-beta-lactamase]-mediated carbapenem resistance is infrequent in the United States, although national surveillance programs have detected blaMBLs in P. aeruginosa and other bacteria,? the researchers wrote. ?At the local and regional level, the early detection of MBL-producing bacteria by clinical microbiology laboratories and their molecular characterization can help inform efforts to prevent and control their dissemination.?
The initial isolate was identified in March 2012 in a patient in a long-term care facility. The patient was a 69-year-old man with type 2 diabetes and the pathogen was found in a foot wound. Six additional patients were affected across three community hospitals, one long-term care facility and one tertiary care center, and one patient died.
The P. aeruginosa pathogen produced the Verona integron-encoded MBL (VIM-2) and was resistant to all fluoroquinolones, aminoglycosides and beta-lactams. Two of the isolates were also non-susceptible to colistin, the typical ?agent of last resort.?
Healio
thanks to Dave Roberts
.
Perez F. - Antimicrob Agents Chemother. 2014;doi:10.1128/AAC.02372-14.
August 17, 2014
Researchers have identified a highly virulent, multidrug-resistant form of Pseudomonas aeruginosa in patient samples in a health care system in Ohio, according to a report in Antimicrobial Agents and Chemotherapy
The pathogen produced metallo-beta-lactamase (MBL), which has remained uncommon in the United States, but is an emerging problem in P. aeruginosa in many other countries.
?Currently, [metallo-beta-lactamase]-mediated carbapenem resistance is infrequent in the United States, although national surveillance programs have detected blaMBLs in P. aeruginosa and other bacteria,? the researchers wrote. ?At the local and regional level, the early detection of MBL-producing bacteria by clinical microbiology laboratories and their molecular characterization can help inform efforts to prevent and control their dissemination.?
The initial isolate was identified in March 2012 in a patient in a long-term care facility. The patient was a 69-year-old man with type 2 diabetes and the pathogen was found in a foot wound. Six additional patients were affected across three community hospitals, one long-term care facility and one tertiary care center, and one patient died.
The P. aeruginosa pathogen produced the Verona integron-encoded MBL (VIM-2) and was resistant to all fluoroquinolones, aminoglycosides and beta-lactams. Two of the isolates were also non-susceptible to colistin, the typical ?agent of last resort.?
Healio
thanks to Dave Roberts
.